GP9

(redirected from CD42a)

GP9

A gene on chromosome 3q21.3 that encodes a surface membrane platelet glycoprotein, which forms a 1-to-1 non-covalent complex with glycoprotein Ib, functioning as a von Willebrand factor receptor. The complete receptor complex consists of alpha subunit, beta subunit (the GP9 product) and platelet glycoprotein V.
References in periodicals archive ?
There is absence of aggregation response with ristocetin on platelet aggregation studies with normal aggregation with other aggregating agents.8 BSS diagnosis is confirmed by Flow cytometric analysis of platelets showing defective binding with CD42a (GPIX), CD42b (GP Ib[alpha]), CD42c (GP Ib[beta]), and CD42d (GPV) antibodies.9 The defective fragments of GP Ib-IX-V complex after separating with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) may be identified by immunobloating.10
Markers D + 0 D + 4 D + 8 D + 11 D + 14 EB D + 14 supernatant OCT4 86.86% 6.8% -- -- -- -- SOX2 98.34% 46% -- -- -- -- NANOG 87.4% 2% -- -- -- -- CD31 -- 0.6% 22.1% 0% -- -- CD144 -- 0.1% 5.7% 0% -- -- CD45 -- 0% 77.2% 0.6% 0.6% 0.8% CD34 APC -- 3.4% 58.3% 27% 24% 30.3% CD135 -- 0% 6.3% 0% 0% 0% CD43 -- 3.4% 29% 10% 0% 0% KDR -- 1% 1.8% 0% -- -- CD235a -- 19% 63.3% 5% 0% 0% CD38 -- -- 52.5% 0% 0% 0% CD117 -- -- 84% 0% 0% 0% CD41a -- -- -- -- 0% 0% CD42a -- -- -- -- 0% 0% EB: embryoid body; APC: allophycocyanin; KDR: kinase insert domain receptor.
PE-conjugated anti-human CD62P, FITC-conjugated anti-human CD42a, REA Control (S)-PE, and REA Control (S)-FITC were from Miltenyi Biotec (Koln, North Rhine-Westphalia, Germany).
The platelets were then separately stimulated with ADP (20 [micro]M), collagen (1 [micro]g/mL), thrombin (0.25 U/mL), and U46619 (2 pM) at 37[degrees]C within 10 min, and then PE-conjugated anti-human CD62P and FITC-conjugated anti-human CD42a were added and incubated for 10 min at 4[degrees]C in the dark.
Furthermore, TNF RI, TLR3, CD42a, CD80, and CD83 as well as Annexin V, Flotillin-1, and Alix were detected on the majority of the plasma sEVs.
Platelet reactivity for different disease pathogenesis is widely dependent upon some biologically active markers like CD36, CD41, CD42a, CD42b, and CD61.
On flow cytometric immunophenotyping, the blasts were positive for CD34, CD45, CD10, CD19, and CD22 and negative for CD3, CD5, CD7 CD13, CD33, CD14, CD42a, CD61, and glycophorin A.
This facilitated identification of the platelets within the blood and was confirmed by the analysis of CD42a expression.